### COVID-19 THERAPY RECOMMENDATIONS TABLE

#### CYTOKINE STORM

<table>
<thead>
<tr>
<th>RECOMMENDATION #41</th>
<th><strong>STRENGTH &amp; QUALITY OF EVIDENCE</strong></th>
</tr>
</thead>
</table>
| In mechanically ventilated adults with COVID-19 and respiratory failure (without ARDS), we **suggest against** the routine use of systemic corticosteroids. | • Weak  
• Low-Quality of Evidence |

<table>
<thead>
<tr>
<th>RECOMMENDATION #42</th>
<th><strong>STRENGTH &amp; QUALITY OF EVIDENCE</strong></th>
</tr>
</thead>
</table>
| In mechanically ventilated adults with COVID-19 and ARDS, we **suggest** using systemic corticosteroids, over not using corticosteroids. | • Weak  
• Low-Quality of Evidence |

<table>
<thead>
<tr>
<th>RECOMMENDATION #43</th>
<th><strong>STRENGTH &amp; QUALITY OF EVIDENCE</strong></th>
</tr>
</thead>
</table>
| In mechanically ventilated patients with COVID-19 and respiratory failure, we **suggest** using empiric antimicrobials/antibacterial agents, over no antimicrobials. | • Weak  
• Low-Quality of Evidence |

<table>
<thead>
<tr>
<th>RECOMMENDATION #44</th>
<th><strong>STRENGTH &amp; QUALITY OF EVIDENCE</strong></th>
</tr>
</thead>
</table>
| For critically ill adults with COVID-19 who develop fever, we **suggest** using acetaminophen/paracetamol for temperature control, over no treatment. | • Weak  
• Low-Quality of Evidence |
### Recommendation #45

In critically ill adults with COVID-19, we **suggest against** the routine use of standard intravenous immunoglobulins (IVIG).

**Strength & Quality of Evidence**
- Weak
- Very Low-Quality Evidence

### Recommendation #46

In critically ill adults with COVID-19, we **suggest against** the routine use of convalescent plasma.

**Strength & Quality of Evidence**
- Weak
- Very Low-Quality Evidence

### Recommendation #47.1

In critically ill adults with COVID-19 we **suggest against** the routine use of lopinavir/ritonavir.

**Strength & Quality of Evidence**
- Weak
- Low-Quality of Evidence

### Recommendation #47.2

There is **insufficient evidence** to issue a recommendation on the use of other antiviral agents in critically ill adults with COVID-19.

**Strength & Quality of Evidence**
- Insufficient

### Recommendation #48

There is **insufficient evidence** to issue a recommendation on the use of recombinant rIFNs, alone or in combination with antivirals, in critically ill adults with COVID-19.

**Strength & Quality of Evidence**
- Insufficient

### Recommendation #49

There is **insufficient evidence** to issue a recommendation on the use of chloroquine or hydroxychloroquine in critically ill adults with COVID-19.

**Strength & Quality of Evidence**
- Insufficient

### Recommendation #50

There is insufficient evidence to issue a recommendation on the use of tocilizumab in critically ill adults with COVID-19.

**Strength & Quality of Evidence**
- Insufficient